Compare · BBNX vs BSX
BBNX vs BSX
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $84.08B, about 179.7x BBNX ($467.9M).
- Over the past year, BBNX is down 29.8% and BSX is down 45.2% - BBNX leads by 15.4 points.
- BSX has been more active in the news (8 items in the past 4 weeks vs 4 for BBNX).
- BSX has more recent analyst coverage (25 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- Boston Scientific Corporation
- Price
- $10.49-0.80%
- $56.58+1.02%
- Market cap
- $467.9M
- $84.08B
- 1M return
- +7.04%
- -9.55%
- 1Y return
- -29.79%
- -45.23%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 8
- Recent ratings
- 16
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BBNX
- Beta Bionics to Present at the Bank of America Securities Health Care Conference
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- SEC Form DEFA14A filed by Beta Bionics Inc.
- SEC Form DEF 14A filed by Beta Bionics Inc.
- Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
- Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)
Latest BSX
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- EVP, Global Operations O'Connor Padraig Andrew converted options into 1,802 shares and covered exercise/tax liability with 872 shares, increasing direct ownership by 15% to 7,024 units (SEC Form 4)
- EVP& Grp Pres, MedSurg & APAC Butcher Arthur C converted options into 2,102 shares and covered exercise/tax liability with 1,007 shares, increasing direct ownership by 2% to 56,887 units (SEC Form 4)
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation